| -- New Data for Response, Survival, and Safety to be Presented at ASCO -- Results Support Projections for New Randomized Trial BERKELEY HEIGHTS, N.J., May 24, 2012 (GLOBE NEWSWIRE) -- Genta Incorporated (GNTA) today announced results from the Company's Phase 2, confirmatory, clinical trial of tesetaxel as 2 nd -line treatment of patients with advanced gastric cancer. The trial was conducted at M.D. Anderson Cancer Center, Houston, TX, in collaboration with Northwestern University, Chica...continued GNTA antisense oncology Healthcare |
Thursday, May 24, 2012
Genta Announces Results of Tesetaxel Confirmatory Trial in Patients With Advanced Gastric Cancer
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment